Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Uchida, Naoyuki
OASIS, NCT05101187: Olorofim Aspergillus Infection Study	Recruiting	3	225	Europe, Canada, Japan, US, RoW	Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)	F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi	Invasive Aspergillosis	09/25	11/26
Fujiwara, Hideaki
OASIS, NCT05101187: Olorofim Aspergillus Infection Study	Recruiting	3	225	Europe, Canada, Japan, US, RoW	Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)	F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi	Invasive Aspergillosis	09/25	11/26
Kanda, Yoshinobu
OASIS, NCT05101187: Olorofim Aspergillus Infection Study	Recruiting	3	225	Europe, Canada, Japan, US, RoW	Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)	F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi	Invasive Aspergillosis	09/25	11/26